- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Bioversys Ag (BIOV)
The Bioversys Ag share price today is 27.50, view SIX BIOV stock exchange data. Track the latest Bioversys Ag share price with real-time updates on BIOV stock performance including market cap, day range, 52-week range and dividend yield. Access BIOV charts, earnings dates and analyst estimates to support your investment decisions.
Switzerland
Currency in CHF
27.50
-0.10(-0.36%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
27.20
27.50
52 wk Range
21.20
35.70
BIOV is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
27.2027.50
52 wk Range
21.2035.70
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
BIOV Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
58.26
Upside
+111.85%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to drop this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 58.26
(+111.85% Upside)
Earnings
Latest Release
03-06-2026
EPS / Forecast
-1.38 / -1.09
Revenue / Forecast
150K / 300K
Compare BIOV to Peers and Sector
Metrics to compare | BIOV | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBIOVPeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.4x | 7.8x | −0.4x | |
PEG Ratio | −0.24 | 0.04 | 0.00 | |
Price/Book | 2.7x | 2.3x | 2.6x | |
Price / LTM Sales | 50.7x | 2.6x | 3.0x | |
Upside (Analyst Target) | 125.5% | 54.1% | 51.7% | |
Fair Value Upside | Unlock | 14.7% | 8.8% | Unlock |
BioVersys AG researches and develops antimicrobial drugs for bacterial infections. It develops BV100 that is in Phase 3 clinical trial for carbapenem-resistant Acinetobacter baumannii lung and bloodstream infections. The company is also developing Alpibectir, which is in Phase 2 clinical trial for the treatment of pulmonary and meningeal tuberculosis; BV200 to treat patients with Gram-positive S. aureus; and BV500 for non-tuberculous mycobacteria infections. It has a research and license option agreement with Shionogi & Co., Ltd. to develop ansamycin leads from the BV500 program into clinical candidates. The company was founded in 2008 and is based in Basel, Switzerland.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Bioversys Ag (BIOV) Share Price Today?
The Bioversys Ag share price today is 27.50.
What is the current Bioversys Ag (BIOV) share price and day range?
As of 12-07-2026, the Bioversys Ag share price is 27.50, with a previous close of 27.60. The share price has ranged from 27.20 to 27.50 today, while the 52-week range spans from 21.20 to 35.70.
What Is the Bioversys Ag Market Cap?
As of today, Bioversys Ag market cap is 161.00M.
What Is the Bioversys Ag (BIOV) Share Price Target?
The average 12-month share price target for Bioversys Ag is 58.26, with a high estimate of 71.3 and a low estimate of 40. 4 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +111.85% Upside potential.
What Is Bioversys Ag's Earnings Per Share (TTM)?
The Bioversys Ag EPS (TTM) is -3.89.
When Is the Next Bioversys Ag Earnings Date?
Bioversys Ag will release its next earnings report on 03-09-2026.
From a Technical Analysis Perspective, Is BIOV a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Bioversys Ag Trade On?
Bioversys Ag is listed and trades on the Switzerland Stock Exchange.
What Is the Stock Symbol for Bioversys Ag?
The stock symbol for Bioversys Ag is "BIOV."
How Many Times Has Bioversys Ag Stock Split?
Bioversys Ag has split 0 times.
How Many Employees Does Bioversys Ag Have?
Bioversys Ag has 33 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.